Brokerages Set Catalent, Inc. (NYSE:CTLT) PT at $63.40

Shares of Catalent, Inc. (NYSE:CTLT) have been assigned an average recommendation of “Hold” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $63.40.

Separately, StockNews.com started coverage on shares of Catalent in a report on Tuesday. They issued a “hold” rating on the stock.

Catalent Price Performance

Catalent stock opened at $63.48 on Tuesday. The firm has a market capitalization of $11.52 billion, a P/E ratio of -28.09, a P/E/G ratio of 2.69 and a beta of 1.15. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent has a twelve month low of $41.15 and a twelve month high of $63.50. The stock’s fifty day simple moving average is $62.69 and its 200-day simple moving average is $60.68.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.10) earnings per share. As a group, equities analysts expect that Catalent will post 0.78 earnings per share for the current fiscal year.

Insider Transactions at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Catalent by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after purchasing an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after buying an additional 229 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in Catalent by 3.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock worth $432,000 after buying an additional 278 shares during the period. GAMMA Investing LLC increased its position in Catalent by 26.9% during the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock worth $79,000 after buying an additional 278 shares during the period. Finally, Blue Trust Inc. lifted its stake in Catalent by 88.7% in the fourth quarter. Blue Trust Inc. now owns 615 shares of the company’s stock valued at $37,000 after buying an additional 289 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.